U.S. Markets open in 7 hrs, 49 mins
| Symbol | Value | Change | Percentage Change |
|---|---|---|---|
| DJIA | 11,632.38 | 29.88 | 0.26% |
| NASDAQ | 2,325.88 | 21.92 | 0.95% |
| S&P 500 | 1,282.19 | 5.19 | 0.41% |
| Day Low 03:10 PM EDT | 69.03 | |
|---|---|---|
| Day High 09:30 AM EDT | 72.40 |
|
| Range | 3.37 | |
| Volume | 7.72 M | |
| 30-Day Avg. Vol. | 5.02 M |
|
| Difference | 53.79% | |
| Market Cap. | 30.7 B | |
| Change | -784.55 M | |
| Shares Out. | 435.86 M | |
| Percent Traded | 1.77% | |
| Revenue | 1.4 B | |
| Earnings | 226.43 M | |
| EPS (TTM) | -3.58 |
| 52-Wk Low 12/20/07 | 41.26 | |
|---|---|---|
| 52-Wk High 10/11/07 | 75.44 |
|
| Range | 34.18 | |
| Prev. Close 7/22/08 | 72.25 | |
| Today's Open | 72.40 | |
| Change | 0.21% | |
| Dividend (TTM) | 0.00 | |
| Div. Yield (TTM) | 0.00% |
|
| Beta | 0.0754 | |
| P/E Ratio (TTM) | — | |
| P/E Ratio (Fwd.) | 42.00 |
A terror from the past has provided hope in the present. Celgene's flagship products Thalomid and Revlimid are versions of the infamous thalidomide, the morning sickness remedy pulled from shelves in the ... View Full Description
| Earnings/Share(EPS) | Estimate | Actual | Difference |
|---|---|---|---|
| 2 Quarters Ago | 0.307 12/31/07 | 0.31 12/31/07 |
0.003
Beat
|
| Last Quarter | 0.339 3/31/08 | 0.36 3/31/08 |
0.021
Beat
|
| Quarterly - 03/31/2008 | Annual - 2007 | |
|---|---|---|
| Total Revenue | 462.60 M | 1.41 B |
| Gross Profit | 408.03 M | 1.28 B |
| Operating Income | 110.70 M | 425.12 M |
| Net Income | -1.64 B | 226.43 M |
Real-Time Quote
